Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

State of viral hepatitis care in 16 countries of Central and Eastern European Region

N. Chkhartishvili, T. Holban, J. Simonović Babić, I. Alexiev, M. Matičič, J. Kowalska, A. Horban, ECEE Network Group

. 2019 ; 27 (3) : 212-216. [pub] -

Language English Country Czech Republic

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19039692

Digital library NLK
Source

E-resources Online Full text

NLK Free Medical Journals from 2004
ProQuest Central from 2009-03-01 to 6 months ago
Medline Complete (EBSCOhost) from 2006-03-01 to 6 months ago
Nursing & Allied Health Database (ProQuest) from 2009-03-01 to 6 months ago
Health & Medicine (ProQuest) from 2009-03-01 to 6 months ago
Public Health Database (ProQuest) from 2009-03-01 to 6 months ago
ROAD: Directory of Open Access Scholarly Resources from 1993

Links

PubMed 31580556
DOI 10.21101/cejph.a5486
Knihovny.cz E-resources

OBJECTIVES: Survey was conducted to assess state of viral hepatitis care in Central and Eastern Europe (CEE). METHODS: Representatives of 16 CEE countries completed on-line survey in April-May 2017 that collected information on basic epidemiology and availability of key services for HCV and HBV infections. Sources of information provided ranged from national surveillance data to expert opinion. RESULTS: The burden of viral hepatitis varied between countries, ranging from 6,500 to 2 million for HCV and from 10,000 to 3 million for HBV. Access to routine HCV RNA testing and genotyping was reported by 11 and 9 countries, respectively. HCV resistance testing was available in 7 countries. Direct acting antivirals (DAAs) were available in 13 countries, most frequently Sofosbuvir and Ledipasvir/Sofosbuvir (12 countries apiece) and Ombitasvir/Paritaprevir/Dasabuvir (9 countries). HBV DNA testing and HBV genotyping were routinely available in 10 and 7 countries, respectively. Eleven countries reported available treatment with Tenofovir. CONCLUSIONS: There are gaps in viral hepatitis care in CEE. Despite the availability of registered modern drugs for HCV and HBV, the access to treatment is limited. Ensuring quality health care is essential to reduce the epidemic and achieve the WHO's goal of eliminating viral hepatitis as a major public health challenge.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19039692
003      
CZ-PrNML
005      
20191113105529.0
007      
ta
008      
191111s2019 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.21101/cejph.a5486 $2 doi
035    __
$a (PubMed)31580556
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Chkhartishvili, Nikoloz $u Infectious Diseases, AIDS and Clinical Immunology Research Centre, Tbilisi, Georgia
245    10
$a State of viral hepatitis care in 16 countries of Central and Eastern European Region / $c N. Chkhartishvili, T. Holban, J. Simonović Babić, I. Alexiev, M. Matičič, J. Kowalska, A. Horban, ECEE Network Group
520    9_
$a OBJECTIVES: Survey was conducted to assess state of viral hepatitis care in Central and Eastern Europe (CEE). METHODS: Representatives of 16 CEE countries completed on-line survey in April-May 2017 that collected information on basic epidemiology and availability of key services for HCV and HBV infections. Sources of information provided ranged from national surveillance data to expert opinion. RESULTS: The burden of viral hepatitis varied between countries, ranging from 6,500 to 2 million for HCV and from 10,000 to 3 million for HBV. Access to routine HCV RNA testing and genotyping was reported by 11 and 9 countries, respectively. HCV resistance testing was available in 7 countries. Direct acting antivirals (DAAs) were available in 13 countries, most frequently Sofosbuvir and Ledipasvir/Sofosbuvir (12 countries apiece) and Ombitasvir/Paritaprevir/Dasabuvir (9 countries). HBV DNA testing and HBV genotyping were routinely available in 10 and 7 countries, respectively. Eleven countries reported available treatment with Tenofovir. CONCLUSIONS: There are gaps in viral hepatitis care in CEE. Despite the availability of registered modern drugs for HCV and HBV, the access to treatment is limited. Ensuring quality health care is essential to reduce the epidemic and achieve the WHO's goal of eliminating viral hepatitis as a major public health challenge.
650    12
$a antivirové látky $x farmakologie $7 D000998
650    _2
$a hepatitida B $x epidemiologie $x prevence a kontrola $7 D006509
650    12
$a hepatitida C $x epidemiologie $x prevence a kontrola $7 D006526
650    _2
$a lidé $7 D006801
651    _2
$a Evropa $x epidemiologie $7 D005060
651    _2
$a východní Evropa $7 D005061
655    _2
$a časopisecké články $7 D016428
700    1_
$a Holban, Tiberiu $u Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova
700    1_
$a Simonović Babić, Jasmina $u Faculty of Medicine Belgrade University, Clinic of Infectious Diseases, Belgrade, Serbia
700    1_
$a Alexiev, Ivailo $u National Centre of Infectious and Parasitic Diseases, Sofia, Bulgaria
700    1_
$a Matičič, Mojca $u University Medical Centre Ljubljana, Ljubljana, Slovenia
700    1_
$a Kowalska, Justyna $u Hospital for Infectious Diseases, Medical University of Warsaw, Warsaw, Poland
700    1_
$a Horban, Andrzej $u Hospital for Infectious Diseases, Medical University of Warsaw, Warsaw, Poland
710    2_
$a ECEE Network Group
773    0_
$w MED00001083 $t Central European journal of public health $x 1210-7778 $g Roč. 27, č. 3 (2019), s. 212-216
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31580556 $y Pubmed
910    __
$a ABA008 $b B 1829 $c 562 $y p $z 0
990    __
$a 20191111 $b ABA008
991    __
$a 20191112100443 $b ABA008
999    __
$a ok $b bmc $g 1464350 $s 1078286
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 27 $c 3 $d 212-216 $e - $i 1210-7778 $m Central European Journal of Public Health $n Cent. Eur. J. Public Health $x MED00001083
LZP    __
$b NLK118 $a Pubmed-20191111

Find record

Citation metrics

Archiving options